Figure 6. Cancer outcomes associated with CD200 expression and NK cell activation.
(A and B) Concordance and differences in prognostic associations between CD200 expression and activated (A) or inactivated (B) NK cells in acute myeloid leukemia (AML), astrocytoma (AC), B cell acute lymphocytic leukemia (B-ALL), breast cancer (BRC), Burkitts lymphoma (BL), chronic lymphocytic leukemia (CLL), colon cancer (CC), diffuse large B cell lymphoma DLBCL, lung adenocarcinoma (LAC), Ewings sarcoma (ES), gastric carcinoma (GC), glioblastoma (GB), head and neck carcinoma (HNC), lung large cell carcinoma (LLCC), lung small cell carcinoma (LSCC), germ cell tumor (GCT), metastatic melanoma (MMET), melanoma primary (MP), multiple myeloma (MM), osteosarcoma (OS), meningioma (M), and ovarian cancer (OC). The r2 values for activated NK cells and inactivated NK cells were 0.28 and 0.12, respectively, as determined using linear regression analysis.